Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Conference summary: ventilator-associated pneumonia.

Jean Chastre1

  • 1Service de Réanimation Médicale, Institut de Cardiologie, Hôpital Pitié-Salpêtrière, 43-87 bd de l'Hôpital, 75651 Paris Cedex 13, France. jean.chastre@psl.ap-hop-paris.fr

Respiratory Care
|June 24, 2005
PubMed
Summary

Ventilator-associated pneumonia (VAP) is a common intensive-care-unit (ICU) infection with high mortality. Effective VAP management requires understanding its causes and implementing multifaceted prevention and antimicrobial therapy strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phenotypic convergence and collateral susceptibility development in Pseudomonas aeruginosa under antibiotic exposure in ICU patients.

npj antimicrobials and resistance·2026
Same author

A consensus of European experts on the definition of ventilator-associated pneumonia recurrences obtained by the Delphi method: the RECUVAP study.

Intensive care medicine·2025
Same author

Subjective and objective survival prediction in mechanically ventilated critically ill patients: a prospective cohort study.

Critical care (London, England)·2023
Same author

Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial.

Critical care (London, England)·2022
Same author

Bronchoscopy for diagnosis of ventilator-associated pneumonia.

Intensive care medicine·2022
Same author

Viral Ventilator-Associated Pneumonia/Hospital-Acquired Pneumonia.

Seminars in respiratory and critical care medicine·2022

Area of Science:

  • Critical Care Medicine
  • Infectious Diseases
  • Hospital Epidemiology

Background:

  • Ventilator-associated pneumonia (VAP) is a frequent intensive-care-unit (ICU)-acquired infection in mechanically ventilated patients.
  • VAP is a subcategory of health-care-associated pneumonia with significant mortality rates (20%-50%), potentially reaching 70%.
  • It prolongs mechanical ventilation and ICU stays, imposing a considerable financial burden.

Framework:

  • VAP pathogenesis and epidemiology are complex, influenced by patient-specific factors and often involving multiple-drug-resistant pathogens.
  • Risk factors for resistant microorganisms include duration of mechanical ventilation, prior antibiotic use, and healthcare system contact.
  • Multifaceted, multidisciplinary programs are essential for effective prevention due to complex respiratory tract colonization.

Related Experiment Videos

Implementation:

  • Antimicrobial therapy for VAP involves a two-stage process: initial broad-spectrum antibiotics followed by de-escalation.
  • Strategies include stopping therapy in low-probability cases, streamlining treatment based on identified pathogens, and switching to monotherapy.
  • Shortening therapy duration to 7-8 days is guided by clinical response and bacteriology.

Implications:

  • Timely, local surveillance data is crucial for guiding preventive measures and understanding VAP causes.
  • Optimizing antimicrobial use is key to combating resistance while effectively treating VAP.
  • A comprehensive approach integrating prevention and tailored therapy is vital for improving patient outcomes and reducing healthcare costs.